“Tackling the growing burden of heart failure: a guide for primary care”
February 27th
This event is for healthcare professionals only.
This webinar has been organised by 3:nine Consulting on behalf of the Alliance for Heart Failure. Astrazeneca, Medtronic, Novartis, and Novo Nordisk have provided sponsorship to 3:nine Consulting to cover the costs of developing and running the webinar. Astrazeneca, Medtronic, Novartis, and Novo Nordisk have had no influence over the meeting agenda or arrangements.
The Alliance for Heart Failure is a coalition of charities, patient groups, professional bodies and healthcare companies working together to raise the profile of heart failure in Government, the NHS and media.

Good medical therapy can greatly improve survival and quality of life among patients with heart failure. The Alliance wants to see life-enhancing and life-saving treatments for heart failure made more widely available through NHS multidisciplinary specialist heart failure teams.
Survival Rate
The survival rate for heart failure is worse than breast or prostate cancer.
900,000 Affected
Heart failure affects over 900,000 people in the UK, with 200,000 new cases annually.
Admissions
Projections indicate that hospital admissions for heart failure are set to rise by 50% in the next 25 years.
Twice as many heart failure patients who are not treated on cardiology wards die (14% of all patients, vs 7%).
Men are more likely to have input from a heart failure specialist or cardiologist than women.
1 in 5 patients admitted to hospital with symptoms of heart failure are not seen by a heart specialist.
Up to 40% of people diagnosed with heart failure die within one year.
Less than a third of patients say their GP ordered a blood test for heart failure.
Heart failure is 1 of 5 long-term conditions responsible for 75% of unplanned hospital admissions.